drugset / Trial / NCT01631071

Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains

NCT01631071

Completed 110 enrolled Crucell Holland BV
RandomizedParallel-groupOpen-labelPrevention

Summary

The study is to assess whether the virosomal influenza vaccine for season 2012/2013 fulfills the EMA requirements for re-registration of influenza vaccines.

Timeline

Start
2012-07
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Inflexal V Vaccine 0.5 ml Intramuscular

Indications